NASDAQ:ARVN

Arvinas (ARVN) Stock Forecast, Price & News

$19.64

-0.15 (-0.76%)

(As of 09/29/2023 ET)

Compare

Today's Range: $19.14
▼
$20.15
50-Day Range: $19.79
▼
$28.21
52-Week Range: $19.14
▼
$57.96

Volume: 471,894 shs
Average Volume: 445,491 shs
Market Capitalization: $1.05 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $64.07

Arvinas MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 226.2% Upside
$64.07 Price Target
Short Interest: Bearish
6.22% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.85
Based on 2 Articles This Week
Insider Trading: Selling Shares
$32,292 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($6.14) to ($7.91) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

356th out of 972 stocks

Pharmaceutical Preparations Industry

151st out of 451 stocks

4.4

Analyst's Opinion

Consensus Rating
Arvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 12 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $64.07, Arvinas has a forecasted upside of 226.2% from its current price of $19.64.
Amount of Analyst Coverage
Arvinas has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
6.22% of the float of Arvinas has been sold short.
Short Interest Ratio / Days to Cover
Arvinas has a short interest ratio ("days to cover") of 7.7.
Change versus previous month
Short interest in Arvinas has recently decreased by 1.04%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Arvinas does not currently pay a dividend.
Dividend Growth
Arvinas does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARVN.

2.7

News and Social Media Coverage

News Sentiment
Arvinas has a news sentiment score of 1.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Arvinas this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,292.00 in company stock.
Percentage Held by Insiders
Only 2.55% of the stock of Arvinas is held by insiders.
Percentage Held by Institutions
86.33% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Arvinas are expected to decrease in the coming year, from ($6.14) to ($7.91) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arvinas is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arvinas is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arvinas has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

ARVN Price History

30 days | 90 days | 365 days | Advanced Chart

ARVN Stock News Headlines

September 8, 2023 | msn.com

Cantor Fitzgerald Reiterates Arvinas (ARVN) Overweight Recommendation

September 4, 2023 | seekingalpha.com

Arvinas' Potential In Treating ER+, HER2- Breast Cancer

September 29, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

August 21, 2023 | msn.com

Citigroup Maintains Arvinas (ARVN) Buy Recommendation

August 17, 2023 | msn.com

Truist Securities Reiterates Arvinas (ARVN) Buy Recommendation

August 14, 2023 | benzinga.com

7 Analysts Have This to Say About Arvinas

August 10, 2023 | msn.com

Barclays Maintains Arvinas (ARVN) Overweight Recommendation

August 9, 2023 | markets.businessinsider.com

Barclays Maintains Overweight Rating for Arvinas: Here's What You Need To Know

September 29, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

August 8, 2023 | finance.yahoo.com

Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 6, 2023 | finance.yahoo.com

Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination

June 26, 2023 | markets.businessinsider.com

What 8 Analyst Ratings Have To Say About Arvinas

June 17, 2023 | finance.yahoo.com

Loss-making Arvinas (NASDAQ:ARVN) has seen earnings and shareholder returns follow the same downward trajectory over past -24%

June 13, 2023 | finance.yahoo.com

Arvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last?

June 12, 2023 | msn.com

Olema, Arvinas spike after analyst remarks on breast cancer drugs

June 12, 2023 | seekingalpha.com

Arvinas: Nothing Interesting In The Near Term

June 10, 2023 | msn.com

Wedbush Reiterates Arvinas (ARVN) Neutral Recommendation

June 9, 2023 | msn.com

HC Wainwright & Co. Reiterates Arvinas (ARVN) Buy Recommendation

June 9, 2023 | markets.businessinsider.com

6 Analysts Have This to Say About Arvinas

June 8, 2023 | markets.businessinsider.com

Bank of America Securities Keeps Their Buy Rating on Arvinas Holding Company (ARVN)

June 8, 2023 | markets.businessinsider.com

Goldman Sachs Keeps Their Buy Rating on Arvinas Holding Company (ARVN)

June 8, 2023 | finance.yahoo.com

Arvinas Releases Early Cut Data Showing Encouraging Efficacy In Prostate Cancer With Certain Mutations

June 8, 2023 | finance.yahoo.com

Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations

May 19, 2023 | msn.com

Looking Into Arvinas's Return On Capital Employed

May 17, 2023 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)

May 13, 2023 | msn.com

Morgan Stanley Maintains Arvinas (ARVN) Equal-Weight Recommendation

May 10, 2023 | msn.com

Where Arvinas Stands With Analysts

See More Headlines

Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Company Calendar

Last Earnings: 8/08/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARVN
CUSIP: N/A
CIK: 1655759
Web: www.arvinas.com
Phone: (203) 535-1456
Fax: N/A
Employees: 415
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $64.07
High Stock Price Forecast: $95.00
Low Stock Price Forecast: $27.00
Forecasted Upside/Downside: +230.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.59)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-282,500,000.00
Net Margins: -191.63%
Pretax Margin: -178.43%
Return on Equity: -55.09%
Return on Assets: -24.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.44
Quick Ratio: 3.44

Sales & Book Value

Annual Sales: $131.40 million
Price / Sales: 7.90
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.61 per share
Price / Book: 1.83

Miscellaneous

Outstanding Shares: 53,490,000
Free Float: 52,121,000
Market Cap: $1.04 billion
Optionable: Not Optionable
Beta: 1.72

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. John G. Houston Ph.D. (Age 63)
Chairperson, CEO & Pres
Comp: $1.08M

Mr. Sean A. Cassidy CPA (Age 53)
CPA, M.B.A., CFO, Principal Financial Officer & Treasurer
Comp: $683k

Dr. Ian Taylor Ph.D. (Age 60)
Chief Scientific Officer
Comp: $692k

Dr. Ronald A. Peck M.D. (Age 57)
Chief Medical Officer
Comp: $701.63k

Mr. David K. Loomis M.B.A. (Age 49)
VP, Principal Accounting Officer & Chief Accounting Officer

Mr. Jeff Boyle
VP of Investor Relations

Dr. Randy Teel Ph.D. (Age 44)
Sr. VP of Corp. & Bus. Devel.

Mr. Steve Weiss (Age 53)
Sr. VP & Chief HR Officer

Dr. John A. Grosso Ph.D. (Age 66)
Sr. VP of R&D Technical Operations

Ms. Angela M. Cacace Ph.D. (Age 55)
Sr. VP of Neuroscience & Platform Biology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARVN Stock - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?: 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.
What is Arvinas' stock price forecast for 2023?: 15 brokers have issued twelve-month price objectives for Arvinas' stock. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they predict the company's stock price to reach $64.07 in the next twelve months. This suggests a possible upside of 230.3% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.
How have ARVN shares performed in 2023?: Arvinas' stock was trading at $34.21 at the beginning of 2023. Since then, ARVN stock has decreased by 43.3% and is now trading at $19.40.
View the best growth stocks for 2023 here.
When is Arvinas' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ARVN earnings forecast.
How were Arvinas' earnings last quarter?: Arvinas, Inc. (NASDAQ:ARVN) released its earnings results on Tuesday, August, 8th. The company reported ($1.25) earnings per share for the quarter, beating analysts' consensus estimates of ($1.65) by $0.40. The firm had revenue of $54.50 million for the quarter, compared to analysts' expectations of $30.94 million. Arvinas had a negative trailing twelve-month return on equity of 55.09% and a negative net margin of 191.63%. Arvinas's quarterly revenue was up 74.1% compared to the same quarter last year. During the same quarter last year, the company earned ($1.32) earnings per share.
What ETFs hold Arvinas' stock?: ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), ALPS Medical Breakthroughs ETF (SBIO), Fidelity Disruptive Medicine ETF (FMED), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE) and

What other stocks do shareholders of Arvinas own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).
When did Arvinas IPO?: (ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.
What is Arvinas' stock symbol?: Arvinas trades on the NASDAQ under the ticker symbol "ARVN."
How do I buy shares of Arvinas?: Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arvinas' stock price today?: One share of ARVN stock can currently be purchased for approximately $19.40.
How much money does Arvinas make?: Arvinas (NASDAQ:ARVN) has a market capitalization of $1.04 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.59) on an earnings per share basis.
How many employees does Arvinas have?: The company employs 415 workers across the globe.
How can I contact Arvinas?: Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.

This page (NASDAQ:ARVN) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial